Kindstar Globalgene Technology Full Year 2024 Earnings: Misses Expectations

Kindstar Globalgene Technology (HKG:9960) Full Year 2024 Results

Key Financial Results

• Revenue: CN¥927.6m (down 4.1% from FY 2023).
• Net loss: CN¥54.6m (down by 232% from CN¥41.3m profit in FY 2023).
• CN¥0.058 loss per share (down from CN¥0.043 profit in FY 2023).

We check all companies for important risks. See what we found for Kindstar Globalgene Technology in our free report.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Kindstar Globalgene Technology Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 30%. Earnings per share (EPS) was also behind analyst expectations.

The primary driver behind last 12 months revenue was the Hematology Testing segment contributing a total revenue of CN¥585.1m (63% of total revenue). Notably, cost of sales worth CN¥484.6m amounted to 52% of total revenue thereby underscoring the impact on earnings. The largest operating expense was Sales & Marketing costs, amounting to CN¥282.2m (46% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of CN¥109.5m. Explore how 9960's revenue and expenses shape its earnings.

The company's shares are up 5.7% from a week ago.

Balance Sheet Analysis

Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. See our latest analysis on Kindstar Globalgene Technology's balance sheet health.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.